FLEETCOR Technologies (FLT) Stock

TORONTO, ON / ACCESSWIRE / December 30, 2024 / Volatus Aerospace Inc. (TSXV:FLT)(OTCQX:TAKOF)(Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or the "Company") has, in line with TSX Venture Exchange (TSXV) guidelines and Volatus Aerospace's commitment to long-term growth, successfully converted $145,545 in preferred shares into common shares. This move, part of the original terms for the acquisition of UAViation Aerial Solutions Ltd in 2020, simplifies the Company's capital structure and enhances shareholder value.

REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Monday, December 9, 2024 at 4:30 pm EST to present data from COVALENT-103, the company's Phase I trial of BMF-500, an investigational covalent FLT3 inhibitor developed using the proprietary FUSION™ System, in adult patients with relapsed or refractory acute leukemia.

– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile –

TORONTO, ON / ACCESSWIRE / October 1, 2024 / Volatus Aerospace Inc. (TSXV:FLT)(OTCQX:TAKOF)(Frankfurt:A3DP5Y/ABBA.F) has been ranked second on the 2024 Canada's Top Growing Companies list, published by The Globe and Mail's Report on Business on September 27th, 2024. The ranking highlights 416 of Canada's fastest-growing businesses, evaluated based on three-year revenue growth.

MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents preliminary data from its ongoing Phase Ib FRIDA study investigating iadademstat in combination with gilteritinib in relapsed/refractory acute myeloid leukemia (AML) patients harboring a FMS-like tyrosine kinase mutation (FLT3 mut+) at the European Hematology Association (EHA) 2024 congress, being held in Madrid (Spain) on June 13–16. Dr. Amir Fathi, from the Massachusetts General Hospital and Principal Investigator of the study, will present a poster communication entitled “Preliminary results of the FRIDA study: iadademstat and gilteritinib in FLT3-mutated R/R AML”.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

FLEETCOR is an overlooked quality company that is currently undervalued. We have used three different valuation methods, and FLT appears undervalued in all three. Despite its high revenue and earnings growth, FLEETCOR has significantly underperformed the S&P 500 in the past five years.

ATLANTA--(BUSINESS WIRE)--FLEETCOR Technologies, Inc. (NYSE: FLT), a leading global business payments company, today announced that the Company will participate in the following investor conferences: On, Wednesday February 21, 2024, the Company will host a fireside chat at the Bank of America Financial Services Conference. The discussion will begin at 12:10 PM ET. On, Wednesday February 28, 2024, the Company will host a fireside chat at the Citi 13th Annual FinTech Conference. The discussion wi.